MYC and medulloblastoma: We recently performed a drug screen that identified kinase inhibitors of the DNA damage response (DDR) pathway and cell cycle machinery as potent agents against MYC-amplified Group 3 medulloblastoma in combination with chemotherapy (Endersby et al., 2021).